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The expression of the plasma membrane Ca2+ ATPase (PMCA) isoforms is altered in 
several types of cancer cells suggesting that they are involved in cancer progression. In this 
study we induced differentiation of MCF-7 breast cancer cells by histone deacetylase 
inhibitors (HDACis) such as short chain fatty acids (SCFAs) or suberoylanilide hydroxamic 
acid (SAHA), and by phorbol 12-myristate 13-acetate (PMA) and found strong upregulation 
of PMCA4b protein expression in response to these treatments. Furthermore, combination of 
HDACis with PMA augmented cell differentiation and further enhanced PMCA4b expression 
both at mRNA and protein levels. Immunocytochemical analysis revealed that the upregulated 
protein was located mostly in the plasma membrane. To examine the functional consequences 
of elevated PMCA4b expression, the characteristics of intracellular Ca2+ signals were 
investigated before and after differentiation inducing treatments, and also in cells 
overexpressing PMCA4b. The increased PMCA4b expression – either by treatment or 
overexpression – led to enhanced Ca2+ clearance from the stimulated cells. We found 
pronounced PMCA4 protein expression in normal breast tissue samples highlighting the 
importance of this pump for the maintenance of mammary epithelial Ca2+ homeostasis. These 
results suggest that modulation of Ca2+ signaling by enhanced PMCA4b expression may 




Plasma membrane Ca2+ ATPases (PMCAs) play an important role in maintaining 
intracellular Ca2+ homeostasis. These pumps are responsible for the expulsion of increased 
intracellular Ca2+ into the extracellular space [1, 2]. The four major isoforms (PMCA1-4) are 
encoded by separate genes and, as a consequence of alternative RNA splicing, more than 20 
variants exist. The different PMCA variants show tissue- and cell-specific expression patterns 
and regulate in different ways the maintenance of the normally low cytosolic Ca2+ 
concentration [3]. Therefore, the expression, localization and activity of the different PMCA 
isoforms need to be precisely controlled to fulfill properly their role [2, 4]. 
Recently several articles have been published that suggest a potential role of intracellular 
Ca2+ homeostasis remodeling in cancer progression [5-7]. However, only a few of them focus 
on the PMCAs [8, 9], and these generally report decreased expression of certain PMCA 
isoforms while increased expression of others in different cancer cells or tissue samples. 
PMCA1b and 4b expression was lower in SV40 transformed human skin and lung fibroblasts 
than in the corresponding parental cell lines [10]. mRNA expression studies on breast cancer 
cell lines showed upreguleted PMCA1 and 2 and downregulated PMCA4 expression in some 
breast cancer cells compared to non-tumorigenic cell lines [11, 12]. PMCA1 was found to be 
epigenetically inactivated in oral squamous cell carcinoma-derived cell lines, and PMCA1 
protein was frequently downregulated in primary oral squamous cell carcinoma and oral 
premalignant lesion tissue samples [13]. Furthermore, downregulation of PMCA4 expression 
in colon carcinoma has been reported while a comparatively high level of PMCA4 was 
detected in normal colon tissue [14, 15]. 
Several lines of evidence have suggested that during differentiation of the tumor cells 
some PMCA isoforms are upregulated. Expression of PMCA 2, 3 and 4 isoforms were 
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enhanced during differentiation of the neuroblastoma cell line IMR-32, and this resulted in 
increased Ca2+ efflux [16]. Short chain fatty acids (SCFAs) are histone deacetylase inhibitors 
that can inhibit proliferation of tumor cells, induce differentiation and apoptosis [17-24]. 
Therefore, several histone deacetylase inhibitors like suberoylanilide hydroxamic acid 
(SAHA, Vorinostat) or valproate (VPA) are used in clinical trials as anticancer drugs [17]. 
Recent experiments demonstrated that SCFA-triggered differentiation upregulated PMCA4b 
expression in a variety of gastric and colon cancer cells [25, 26]. The protein kinase C 
activator phorbol 12-myristate 13-acetate (PMA) has also been shown to cause differentiation 
in MCF-7 cells [20-22], and as suggested by others it can induce PMCA mRNA and protein 
expression in vascular endothelial cells [27]. 
In this study we examined the effect of HDACis and PMA on the expression of PMCAs in 
the MCF-7 cell line which is a commonly used breast cancer model for studying the 
mechanisms of tumor progression. We found marked PMCA4b upregulation during HDACi-
induced differentiation that was further enhanced by PMA, while there were no remarkable 
changes in the expression levels of the other PMCA isoforms. The increased PMCA4b 
expression led to enhanced Ca2+ clearance from the cells stimulated with various calcium 
mobilizing agents. PMCA4 protein was also found in normal breast epithelial cells, 
suggesting that this protein plays a role in the regulation of Ca2+ homeostasis of the mammary 
epithelium. 
 
2. Materials and methods 
 
2.1. Cell culture 
The MCF-7 breast cancer cell line (ATCC HTB-22) was obtained from The American 
Type Culture Collection, and was cultured in DMEM supplemented with 10% FBS, 100 U/ml 
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penicillin, 100 μg/ml streptomycin and 2 mM glutamine at 37°C and 5% CO2 in a humidified 
atmosphere. 
 
2.2. Treatments of MCF-7 cells 
Short chain fatty acids (butyric acid, 4-phenylbutyric acid and valeric acid; purchased 
from Sigma-Aldrich) were dissolved at 300 mM concentration in equimolar sterile sodium 
bicarbonate solution then membrane filtered using a 0.2 μm filter and stored at -20°C. 
Valproic acid sodium salt (Sigma-Aldrich) was dissolved at 200 mM concentration in sterile 
distilled water, membrane filtered and stored at -20°C. Phorbol 12-myristate 13-acetate 
(PMA; Sigma-Aldrich), suberoylanilide hydroxamic acid (SAHA; Sigma-Aldrich) and GF 
109203X hydrochloride (Sigma-Aldrich) stock solutions were made in DMSO and stored at -
20°C. Exponentially growing cells were seeded at 1.5-2×105 cells/well in 6-well plates for 
Western blot and real time PCR analysis, at 8-9×104 cells/well in 24-well plates for analysis 
of cell proliferation and Oil Red O staining, at 3-4×105 cells per 6 cm diameter Petri dishes 
for immunoprecipitation and at 0.8-1×105 cells/well in Imaging Chamber CG 8 Well (PAA) 
for immunostaining and Ca2+ signal measurements. When cultures reached 80% confluency, 
medium was replaced by fresh DMEM and differentiation inducing drugs were added from 
concentrated stock solutions. During SAHA treatment the medium was replaced daily. The 
final DMSO concentration did not exceed 0.01% in all experiments, DMSO vehicle was 
included in controls and did not interfere with the experiments. 
 
2.3. Transfection 
Transient transfection with the mCherry-PMCA4x/b construct [28] was carried out using 




2.4. Generation of the stable GCaMP2-MCF-7 cell line 
To establish an MCF-7 cell line stably expressing the genetically encoded Ca2+ sensor 
GCaMP2, we used the Sleeping Beauty transposon system [29, 30]. Cells were cotransfected 
with the SB100× transposase plasmid and the SB-CAG-GCaMP2-CAG-Puro transposon 
construct [31] that contains a puromycin resistance gene, at a 1:10 ratio using FuGENE HD 
Transfection Reagent (Roche Applied Science). Two days post-transfection, culture medium 
was replaced by fresh medium containing 1 μg/ml puromycin dihydrochloride (Santa Cruz 
Biotechnology) and selection was continued until all of the non-transfected cells died. During 
the selection period cells were monitored for GFP fluorescence using a fluorescent 
microscope, and medium was replaced by freshly made selective medium in every two days. 
The resulting polyclonal GCaMP2-MCF-7 cell line was used for Ca2+ signal measurements. 
 
2.5. Cell proliferation 
To examine cell proliferation, equal numbers of cells were treated with the indicated 
differentiating compounds for 4 days. After treatments, cells were washed twice with PBS, 
trypsinized and live cells were counted using an automated cell counter (Bio-Rad). Viability 
was assessed by the trypan blue exclusion method. Untreated control cells were counted 
before, and 4 days after treatments, as indicated. 
 
2.6. Oil Red O staining 
Cells were treated with the indicated differentiating agents for 4 days, then were washed 
twice with PBS and fixed with 4% paraformaldehyde in PBS for 15 min at 37°C. After 
washing two times with distilled water, cells were incubated with 60% isopropanol for 2 min, 
and then stained with Oil Red O (Sigma-Aldrich) dissolved at 1.8 mg/ml in 60% isopropanol, 
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for 10 min. Phase contrast and fluorescent images were captured with an Olympus CKX41 
microscope using a 40× objective. Cell number and total area of lipid droplets per image were 
determined using the ImageJ software v1.42q. 
 
2.7. Western blot analysis 
Total protein from treated cells was precipitated by the addition of 6% TCA and was 
analyzed by Western blot as described previously [32]. Equal amounts of protein were loaded 
on 7.5% acrylamide gels, electrophoresed, electroblotted onto PVDF membranes (Bio-Rad) 
and immunostained. The following primary antibodies were used: mouse monoclonal anti-
pan PMCA (5F10; dilution 1:5000), rabbit polyclonal anti-PMCA1 (NR1; dilution 1:500), 
rabbit polyclonal anti-PMCA2 (NR2; dilution 1:500), rabbit polyclonal anti-PMCA3 (NR3; 
dilution 1:500) and mouse monoclonal anti-PMCA4b (JA3; dilution 1:1000) described in [33, 
34], rabbit polyclonal anti-PMCA1 (Affinity BioReagents, PA1-914; dilution 1:1000), mouse 
monoclonal anti-SERCA2 antibody (IID8; dilution 1:2500) obtained from Sigma-Aldrich 
(S1439), mouse monoclonal anti-SERCA3 (PL/IM430; dilution 1:200) described in [25] and 
mouse monoclonal anti-Na,K-ATPase (dilution 1:2000) from Enzo Life Sciences (BML-
SA247). Subsequently, HRP-conjugated anti-mouse or anti-rabbit secondary antibodies 
(Jackson ImmunoResearch) were applied and detected by Pierce ECL Western Blotting 




Cells were treated with 2 mM valerate in the presence or absence of 10 nM PMA for 4 
days. PMCA proteins from whole cell lysates were enriched by immunoprecipitation with the 
5F10 anti-pan PMCA antibody using the Pierce Co-Immunoprecipitation Kit (Thermo 
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Scientific). The experimental procedure was done according to the manufacturer’s 
instructions except that the electrophoresis sample buffer contained 0.1 M dithiothreitol, 0.8 
M urea and 5 mM EDTA-Na pH 6.8, and heating of the samples was omitted. 
 
2.9. Real-time quantitative PCR 
Cells were treated with 2 mM valerate in the presence or absence of 10 nM PMA for 4 
days, and then total RNA was isolated with the peqGOLD TriFast reagent (Peqlab 
Biotechnologie) and subsequently reverse transcribed using the Reverse Transcription System 
(Promega) according to the instructions of the suppliers. Amplification of cDNA was 
performed using StepOnePlus Real-Time PCR System (Applied Biosystems) with TaqMan 
Gene Expression Master Mix and the following TaqMan Gene Expression Assays: 
Hs00155949_m1 for PMCA1, Hs01090453_m1 for PMCA2 and Hs00608066_m1 for 
PMCA4 (Applied Biosystems). Reactions were run under standard cycling conditions 
according to the supplier's recommendations. Quantitation of PMCA mRNA levels was done 
by StepOne software v2.1 (Applied Biosystems) according to the comparative CT method, 




After treatment with 2 mM valerate ± 10 nM PMA for 4 days cells were washed twice 
with 37°C HBSS and fixed with 4% paraformaldehyde for 15 min at 37°C. After five washes 
with PBS, cells were permeabilized with ice cold methanol for 5 min and washed five times 
again with PBS. Subsequently, cells were incubated in blocking buffer (PBS containing 2 
mg/ml bovine serum albumin, 1% fish gelatin, 0.1% Triton-X 100, 5% goat serum) for 1 h at 
RT and then immunostained with a mouse monoclonal anti-PMCA4b antibody (JA3; dilution 
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1:100) or a mouse monoclonal anti-PMCA4 antibody (JA9; dilution 1:100) [33] and with a 
chicken polyclonal anti-Na,K-ATPase antibody (Abcam, ab353; dilution 1:500) for 1 h at RT. 
After three washes with PBS, cells were incubated with Alexa Fluor anti-mouse and anti-
chicken secondary antibodies (Invitrogen) for 1 h at RT and imaged with an Olympus IX-81 
confocal laser scanning microscope and Fluoview FV500 software v4.1 using an Olympus 
PLAPO 60× (1.4) oil immersion objective. All images were taken with the same microscope 
settings. 
 
2.11. Ca2+ signal measurements 
GCaMP2-MCF-7 cells were treated with 2 mM valerate ± 10 nM PMA for 3 days, then 
the medium was replaced by fresh DMEM and cells were incubated in the absence of 
differentiating compounds for an additional day. For comparison, untreated GCaMP2-MCF-7 
cells were transiently transfected with the mCherry-PMCA4x/b construct 2 days before Ca2+ 
signal measurements. Prior to the experiments cells were incubated for two hours in phenol 
red-free DMEM containing 10 mM HEPES pH 7.4 and 10% FBS. To measure store-operated 
Ca2+ entry, medium was replaced by nominally Ca2+ free HBSS supplemented with 0.9 mM 
MgCl2, 100 μM EGTA, 100 μM CaCl2 and 20 mM HEPES pH 7.4. Intracellular stores were 
depleted with 2 μM thapsigargin and subsequently with 100 μM ATP. After 5 min the 
external Ca2+ was restored to 2 mM by the addition of CaCl2 and Ca2+ influx through store-
operated Ca2+ channels was followed for 10 min. When Ca2+ signals were evoked by A23187, 
first the medium was replaced by HBSS supplemented with 0.9 mM MgCl2, 2 mM CaCl2 and 
20 mM HEPES pH 7.4, and then Ca2+ influx was triggered by the addition of 2 μM A23187. 
Images were taken with an Olympus IX-81 confocal laser scanning microscope and Fluoview 
FV500 software v4.1 using an Olympus PLAPO 60× (1.4) oil immersion objective. For 
GCaMP2 imaging cells were excited at 488 nm and emission was collected between 505 and 
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535 nm. mCherry-PMCA4x/b was illuminated at 543 nm and emission above 560 nm was 
recorded. Images were acquired every 0.3 s, z-resolution was 1 μm.  Time lapse sequences 
were recorded with Fluoview Tiempo time course software v4.3 at RT. The relative 
fluorescence intensities were calculated as F/F0 (where F0 was the average initial 
fluorescence) and data were analyzed with the Prism 4 software v4.01 (GraphPad Software). 
 
2.12. Immunohistochemistry 
Immunohistochemical staining for PMCA4 was performed with the JA9 mouse IgG1 
monoclonal antibody (Sigma-Aldrich, P1494) on 5 μm thick deparaffinized formalin-fixed 
sections using an indirect avidin-biotin-peroxydase method and 3,3’diaminobenzidine as 
chromogene. Immunstaining was performed on a Benchmark automatic immunstainer 
(Ventana Medical Systems), and inhibition of endogeneous peroxidase activity, biotin block 
and signal amplification were performed according to the protocol of the manufacturer. 
Antigen retrieval of deparaffinized sections by a tris-(hydroxymethyl)-aminomethane-based 
antigen retrieval reagent (Ventana CC1 cell conditioning solution) was done at 95-100°C for 
30 min, and slides were incubated with the anti-PMCA4 antibody in Emerald Antibody 
Diluent (Cell Marque) at 3 μg/ml for 30 min at 37°C. Staining was revealed using the Ventana 
I-View Biotin-Ig-streptavidin-horseradish peroxydase system with copper enhancement, 
according to the instructions of the manufacturer, and slides were counterstained with 
hematoxylin. In control experiments slides were stained with 3 μg/ml of an irrelevant IgG1 
monoclonal antibody at identical conditions, and this gave no staining. 
 
2.13. Statistical analysis 
Data were analyzed with Prism 4 software v4.01 (GraphPad Software) and are expressed 
as means ± SD, except for the Ca2+ signal measurements where they are means ± 95% CI. 
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Statistical significance was calculated by t-test, *** means P<0.001, ** means P<0.01, * 




3.1. SCFAs and PMA enhanced the expression of PMCA4b in MCF-7 cells 
SCFAs such as butyrate and its aryl-substituted analog phenylbutyrate are known 
differentiating agents in several experimental systems [20-24]. Moreover, they have been 
shown to enhance PMCA4b expression in colon cancer cells [25, 26]. In addition PMA has 
been suggested to induce differentiation of MCF-7 cells [20-22]. Therefore, we examined the 
effects of these differentiation inducing compounds on PMCA expression in MCF-7 cells 
[35]. After treating cells with butyrate, phenylbutyrate, valerate (SCFAs) or with PMA, the 
expression of PMCA isoforms was determined by Western blot analysis. Fig. 1A-D shows 
changes of PMCA protein levels at increasing concentrations of SCFAs and PMA. The 5F10 
anti-pan PMCA antibody recognized two bands of which the upper band was also selectively 
detected by the anti-PMCA1 antibody while the lower band by the PMCA4b specific 
antibody JA3. PMCA1 was the main PMCA isoform in untreated MCF-7 cells but the 
expression pattern changed rather dramatically after treatments. Both SCFAs and PMA 
induced marked upregulation of PMCA4b expression without having much effect on the 
expression of the PMCA1 isoform. The level of Na,K-ATPase expression remained constant 
during the treatments and served as a control in further experiments. The increase of PMCA4b 
expression was maximal at 3-5 mM of the SCFA compounds used, and at 10 nM of PMA. 
Fig. 1E represents a time course of the treatments with the maximally effective SCFA and 
PMA concentrations (5 mM of butyrate, phenylbutyrate (PB) and valerate or 10 nM of PMA, 
as indicated). Increased PMCA4b expression could be detected as early as days 1 or 2 and the 
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protein expression reached a plateau-phase around the 4th day of treatment. The relative 
amount of PMCA4b (stained with antibody JA3, Fig. 1F) and total PMCA (i.e. PMCA1 and 
PMCA4 together stained with antibody 5F10, Fig. 1G) expressions were further assessed by 
semi-quantitative densitometric analysis of the Western blots. The level of PMCA4b protein 
was greatly enhanced (50-90 fold) during the treatments that resulted in a substantial increase 
(6-10 fold) of the overall PMCA protein expression. 
 
3.2. Effects of SCFAs and PMA on cellular proliferation and differentiation 
It is widely accepted that SCFAs inhibit cell proliferation and at higher concentrations 
induce apoptosis in various cancer cells [36-41] whereas, the effect of PMA on cell survival 
and proliferation appears to be more diverse; it depends on the contributing PKC isoform, the 
activity of interacting signaling pathways and the duration of treatment [21, 42-46]. Here we 
examined the proliferation rate of cells during a prolonged treatment (4 days) with SCFAs or 
PMA. Equal numbers of cells were treated with the appropriate compound and viable cells 
were counted using the trypan blue exclusion method. Fig. 2A shows that all SCFAs inhibited 
cell proliferation, and at higher concentrations (5 mM) significantly reduced the number of 
viable cells. A time course of the viability assay (Fig. 2B) shows that at a lower concentration 
of valerate (2 mM) growth inhibition was less pronounced and significant cell death could be 
detected only after longer incubation times. Therefore, in further experiments we treated cells 
with valerate instead of butyrate or phenylbutyrate because it resulted in more viable cells as 
it was shown previously [23, 24]. The proliferation of PMA treated cells was also diminished, 
however, no significant decrease of viability was observed during the 4 day treatment 
suggesting that in accordance with previous reports, PMA inhibited growth but did not cause 
significant cell death [44]. 
13 
 Differentiation results in the intracellular accumulation of Oil Red O positive lipid 
droplets which is a widely used phenotypic marker of differentiation in breast cancer cells 
[20, 22, 47]. Therefore, we used the Oil Red O staining procedure to verify the differentiation 
status of MCF-7 cells after exposure to SCFAs or PMA (Fig. 2C-E). Areas of lipid droplets 
per cells were determined using the ImageJ software (Fig. 2C,D). All treatments resulted in a 
great increase in the population of Oil Red O positive cells so that the area of lipid droplets 
per cell increased 9-15 fold in SCFA-treated cells compared to control. Previous studies 
showed that SCFA and PMA treatments acted synergistically in colon cancer [48] and 
intestinal epithelial cells [49], therefore, we tested the differentiation status of MCF-7 cells 
treated with SCFAs in combination with PMA. We found that PMA greatly potentiated the 
differentiation process induced by valerate (Fig. 2C-E) and maximal induction could be 
reached between day 2-3 (Fig. 2D). 
 
3.3. Combined treatment by valerate and PMA further increased PMCA4b upregulation in 
MCF-7 cells 
Our experiments showed that PMA potentiated SCFA-induced differentiation of MCF-7 
cells; therefore, we tested how the combination of these treatments influenced PMCA 
expression. In these experiments we used valerate together with PMA and followed PMCA 
expression for up to 3 days. Fig. 3A-D demonstrates that the combined treatment highly 
augmented the upregulation of PMCA4b protein expression. A comparison of the time curves 
in Fig. 3D and Fig. 2D shows that both PMCA4b expression and cell differentiation reached 
their maximum level between day 2-3 suggesting correlation between these processes. 
Other key factors of cellular Ca2+ homeostasis are the sarco/endoplasmic reticulum Ca2+ 
ATPases (SERCAs). Therefore, we examined changes in the expression level of the SERCA-
type Ca2+ pumps in valerate ± PMA-treated MCF-7 cells (Fig. 3A). A significant increase of 
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SERCA2 expression was observed when cells were treated with PMA alone, while SERCA3 
levels increased in valerate-treated cells. These results are in agreement with earlier data 
showing reduced SERCA3 expression during breast epithelial tumorigenesis [50] and 
upregulated SERCA3 expression by SCFAs in several lung and colon cancer cell lines [51, 
52]. 
To further characterize the PMCA expression pattern in MCF-7 cells PMCA proteins 
were specifically enriched by immunoprecipitation with the 5F10 anti-pan PMCA antibody, 
and samples were tested for the expression of all PMCA isoforms using isoform specific 
antibodies (Fig. 3E). The results of these experiments further support our data shown in Fig. 
1A-D that PMCA1 was the major isoform in untreated MCF-7 cells, and that its expression 
did not increase after the treatments. On the other hand, while the expression of PMCA4b was 
relatively low in control cells, it was highly upregulated upon treatments. In contrast to 
previous findings [53], we could not detect PMCA2 (neither PMCA3) protein expression 
either in control or treated MCF-7 cells using isoform specific antibodies (NR2 and NR3). 
 
3.4. Valerate and PMA induced upregulation of PMCA4b mRNA expression in MCF-7 cells 
To support our findings at the protein level we also examined changes in the mRNA 
expression of PMCA1, 2 and 4 during valerate ± PMA-induced differentiation of MCF-7 cells 
(Fig. 3F). The mRNA expression of PMCA1 and PMCA2 was not affected significantly by 
the treatments, whereas PMCA4 mRNA expression showed marked upregulation (6.7- and 
5.4-fold increase in valerate- and PMA-treated cells, respectively, and a large, 34.3-fold 
increase in valerate plus PMA-treated cells). This correlates well with the enhanced PMCA4b 
protein expression detected in differentiated MCF-7 cells. 
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3.5. PKC inhibitor GF 109203X diminished the PMA- but not the valerate-induced 
upregulation  of PMCA4b expression  
To gain more insight into the mechanisms of treatments, we supplemented the 
differentiation-inducing media with the PKC inhibitor GF 109203X hydrochloride to 
selectively inhibit PKC mediated pathways [54]. Fig. 3G shows that the inhibitor nearly 
completely abrogated the PMCA4b upregulation induced by PMA, while the PMCA4b 
expression decreased only slightly in valerate-treated cells. A more pronounced inhibition was 
observed in cells treated with valerate in combination with PMA, although, no complete 
inhibition could be detected when valerate was present in the incubation medium. These 
results suggest that SCFAs and PMA act through different pathways and that PKC is most 
probably not involved in SCFA-induced PMCA upregulation. 
 
3.6. Subcellular localization of PMCA4b in MCF-7 cells 
Previous studies have reported the expression of the PMCA4b isoform in rat mammary 
gland by RT-PCR [55-57]. Therefore, in most of our studies we used the PMCA4b specific 
antibody JA3 that recognized specifically the “b” splice variant of PMCA4. To test if the “a” 
splice variant of PMCA4 was also present in these cells, immunostaining was performed 
using the PMCA4 antibody JA9 that recognizes both the “a” and “b” variants. Samples 
overexpressing both splice variants, PMCA4b and PMCA4a, were used as PMCA markers. 
The Western blots in Fig. 4A clearly demonstrate that the PMCA4b variant is expressed in 
MCF-7 cells (the upper band in Fig. 4A, lower panel), which is in agreement with previous 
studies [55-57]. To examine the localization of the upregulated PMCA4b protein, 
immunocytochemical staining with the isoform and variant specific antibodies (JA9 and JA3, 
respectively) was performed on valerate ± PMA-treated cells and was analyzed by confocal 
microscopy (Fig. 4B). PMCA4 expression in the untreated cells was hardly detectable. Under 
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the same microscope settings, treatment of the cells with valerate or PMA alone increased the 
PMCA4 signal, and in agreement with the above findings the combined treatment (valerate 
plus PMA) caused an even higher PMCA4 signal. Moreover, both the PMCA4 (JA9) and 
PMCA4b (JA3) specific staining showed clear plasma membrane localization so that the 
newly expressed pump is expected to be functional. The signal intensity of the Na,K ATPase 
staining did not change significantly upon treatments. 
 
3.7. Effective treatment of cells by SAHA and valproate highlights the importance of histone 
deacetylase inhibitors in PMCA4b upregulation 
Because of the anticancer activity of HDACis, some of them are approved by the Food 
and Drug Administration (FDA), or they are used in clinical trials either alone or in 
combination with other drugs [17]. Therefore, we examined whether these inhibitors affected 
PMCA4b expression in MCF-7 cells. Cells were treated by SAHA and valproate alone or 
together with PMA, and PMCA expression was followed. Fig. 5 shows that these HDACis, 
similarly to the SCFAs, remarkably upregulated PMCA4b protein expression (5-10 fold). On 
the other hand, a slight increase of PMCA1 expression could also be detected. The combined 
SAHA + PMA or valporate + PMA treatments augmented the PMCA4b upregulation 
similarly to that seen with valerate. SAHA and valproate further enhanced PMCA4b 
expression of PMA-treated cells by about two-fold. 
 
3.8. Regulation of Ca2+ clearance by PMCA4b in differentiated MCF-7 cells 
To study how upregulation of PMCA4b affected Ca2+ signaling in breast cancer cells, we 
established an MCF-7 cell line stably expressing the genetically encoded calcium sensor 
GCaMP2 (GCaMP2-MCF-7 cells) using the Sleeping Beauty transposon system. A 
representative image of the GCaMP2-MCF-7 cells is shown in Fig. 6A. The GCaMP2 
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expressing cells were treated with valerate ± PMA for 3 days and then fresh medium (without 
valerate or PMA) was added a day before performing the Ca2+ signaling experiments. Fig. 6B 
indicates that in response to valerate ± PMA treatments PMCA4b expression was highly 
elevated (60-600 fold, data not shown) in the GCaMP2-MCF-7 cells similarly to that found in 
the parental MCF-7 cell line (Fig. 1 and 3). This high level of endogenous PMCA4b 
expression was comparable with that obtained by transient expression of mCherry-tagged 
PMCA4b in non-treated GCaMP2-MCF-7 cells. 
We performed Ca2+ signal measurements by confocal imaging in GCaMP2-MCF-7 cells 
differentiated with valerate ± PMA. Before initiating the Ca2+ signal the culture medium was 
replaced with Ca2+ free medium, and then intracellular Ca2+ pools were discharged by the 
SERCA-inhibitor thapsigargin (Tg) and the purinergic receptor agonist, ATP. After 5 minutes 
the external Ca2+ was restored to 2 mM and Ca2+ influx through store-operated Ca2+ channels 
was followed for an additional 10 minutes. The average relative fluorescence intensities of 
Ca2+ transients in Fig. 6C show that the intracellular Ca2+ concentration returned quickly to 
baseline level in differentiated cells after both ATP-induced stimulus and store operated Ca2+ 
entry (SOCE), while a more sustained Ca2+ peak was observed in the untreated control cells. 
Similarly, when the signal was initiated by the Ca2+ ionophore A23187 that evokes Ca2+ 
influx independent of the Ca2+ channels, a smaller Ca2+ peak was observed in valerate ± 
PMA-differentiated cells than in control cells (Fig. 6D). After each experiment cells were 
fixed and stained with anti-PMCA4 antibody to show that PMCA4b expression was enhanced 
and the pump was localized correctly after the differentiating treatments. In Fig. 6E 
representative images of valerate ± PMA-treated cells are shown after the Ca2+ signal 
measurement. The enhanced Ca2+ clearance observed in these experiments is in good 
agreement with the elevated expression and proper plasma membrane localization of a 
functional PMCA4b protein in differentiated MCF-7 cells. Based on these results, we can not 
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rule out the contribution of other Ca2+ fluxes, however, the A23187-induced Ca2+ signal 
measurements suggest that changes in the activity of the Ca2+ entry channels may not be 
responsible for the reduced Ca2+ signal. 
 
3.9. Regulation of Ca2+ clearance in PMCA4b overexpressing MCF-7 cells 
To study further the role of PMCA4b in Ca2+ signaling we performed Ca2+ signal 
measurements with the GCaMP2-MCF-7 cells transiently transfected with the mCherry-
PMCA4x/b construct. Importantly, the level of mCherry-PMCA4x/b overexpression was 
similar to that of the upregulated endogenous PMCA4b in differentiated cells permitting 
comparison of the data (Fig. 6B). As demonstrated by the images in Fig. 7A, the mCherry 
signal helped us identify the PMCA4b overexpressing cells. The diagram in Fig. 7B shows 
the average relative fluorescence intensities of the Tg- and ATP-induced signals in the 
absence of extracellular calcium followed by SOCE in mCherry-PMCA4x/b transfected cells. 
The pattern of the Ca2+ signal was very similar to that of the differentiated cells as the 
intracellular Ca2+ concentration returned much faster to the baseline level in PMCA4b 
overexpressing cells than in the control cells. The half-time from the decay phase of the 
SOCE transient were determined for each situation (i.e. treatments with valerate and PMA 
and overexpression of the PMCA4b). The bar graph in Fig. 7C shows a significantly shorter 
half peak decay time of the SOCE transient for cells with an enhanced PMCA4b level than for 
control cells with much lower PMCA4b expression. Importantly, the half peak decay time of 
the valerate ± PMA differentiated cells was comparable to the cells overexpressing mCherry-
PMCA4x/b. Also, similarly to the differentiated cells, the A23187-induced Ca2+ transient was 
smaller in the PMCA4b overexpressing cells than in the control cells (Fig. 7D). Thus, 
overexpression of the PMCA4b protein resulted in similar changes in the Ca2+ signaling 
pattern as the upregulated endogenous pump, suggesting that the PMCA4b protein 
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endogenously overexpressed during differentiation is critically involved in the Ca2+ clearance 
of differentiated MCF-7 cells and thus contributes to cellular Ca2+ homeostasis. However, 
further studies are needed to assess the impact of each contributor Ca2+ channel and pump in 
the regulation of Ca2+ homeostasis of differentiated MCF-7 cells. 
 
3.10. PMCA4 expression in normal breast tissue 
PMCA4 expression in normal human breast ductal epithelium was investigated with the 
JA9 PMCA4-specific monoclonal antibody by immunohistochemistry. As shown in Fig. 8, 
staining with this antibody led to the labeling of breast ductal epithelial cells. The pattern of 
PMCA4 staining was compatible with location in the plasma membrane. The detection of 
PMCA4 in the plasma membrane of normal mammary epithelium indicates that this calcium 
pump species is involved in calcium homeostasis of normal breast epithelial cells, and that 
decreased expression in breast carcinoma, as well as induction of expression during cancer 




Remodeling of intracellular Ca2+ homeostasis is an important step of tumorigenesis, since 
intracellular Ca2+ signals play role in cell-cycle progression, apoptosis, cell migration and 
metastasis formation [7, 8]. In breast cancer cells store-operated Ca2+ channels are essential 
for migration and invasion [58], and epithelial-mesenchymal transition can also be regulated 
through SOCE in MCF-7 cells [59]. Further, SOCE is involved in the apoptosis-inducing 
effect of butyrate in colon cancer cells [60]. Several lines of evidence suggest that PMCAs, 
that are known  to reduce intracellular Ca2+ concentration after stimuli, are also involved in 
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the remodeling of Ca2+ homeostasis during the differentiation/dedifferentiation process [14, 
15, 25, 26]. 
In this study we investigated the effect of differentiation-inducing agents on the 
expression and function of PMCAs in MCF-7 cell line. Aberrant HDAC expression initiates 
tumor progression by causing uncontrolled cell proliferation and blocking the transcription of 
differentiation and proapoptotic factors [19]. HDACis, which are known differentiating 
compounds, restore the normal gene expression of cancer cells by altering transcription levels 
of cell cycle regulatory proteins; they induce the expression of the antiproliferative gene p21, 
regulate the activity of the tumor suppressor p53, and reduce the expression of positive 
regulators of proliferation, such as cyclin D1, c-myc and c-Src [17, 18]. The PKC activator 
PMA directly induces the Raf-MEK-ERK signaling pathyway, that further activates the cell-
cycle inhibitor p21 and diminishes cell growth [61]. During HDACi- or PMA-induced 
differentiation we found marked PMCA4b upregulation both at the mRNA and protein levels, 
while there were no significant changes in the expression of the other PMCA isoforms. 
PMCA4b expression and differentiation of cells was greatly enhanced when we combined 
valerate with PMA. Our experiments suggest that these agents act via different mechanisms 
since PMA-induced PMCA4b upregulation was abrogated by a PKC inhibitor while SCFA-
induced upregulation was only slightly modified by PKC inhibition. Similarly to our findings 
in MCF-7 cells, PMA augmented butyrate-induced differentiation in colon cancer cells but the 
butyrate-induced differentiation was not inhibited by PKC inhibitors [48]. A more recent 
study also proves that butyrate-induced cellular processes can be potentiated by PMA. In 
intestinal epithelial cells SCFAs and PMA activated synergistically the AP-1 transcription 
factor through the ERK1/2 signaling pathway, which is an important regulator of cell 
proliferation, differentiation, migration and apoptosis [49]. An interesting finding of this study 
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was that PMA alone activated the AP-1 through PKC and MEK1/2, while activation by 
butyrate depended only on MEK1/2. 
Correspondingly, expression of SERCA3, a sarco/endoplasmic reticulum-type Ca2+ pump 
is also increased during SCFA-induced differentiation of lung and colon cancer cells [51, 52], 
indicating that remodeling of Ca2+ homeostasis is important in cancer progression and affects 
more components of the Ca2+ handling toolkit. We also found a slight elevation of SERCA3 
expression in valerate-treated MCF-7 cells, while PMA induced upregulation of SERCA2. 
PMCA2 is a hallmark of the lactating mammary gland but its expression is rapidly 
downregulated during mammary gland involution, and in non-lactating mammary gland 
PMCA4b is the major PMCA isoform [55-57]. A recent study showed that elevated PMCA2 
expression in mammary epithelial cells inhibited apoptosis and in human breast cancer cases a 
high PMCA2 mRNA level was associated with poor clinical prognosis [62]. In breast cancer 
cell lines PMCA1 and PMCA2 was shown to be expressed at an increased level compared to 
non-tumorigenic cells [11, 12] although, in one study PMCA2 mRNA was not detected by 
RT-PCR in MCF-7 cells [63]. By real-time quantitative PCR we also observed the expression 
of all three PMCA isoforms (PMCA1, 2 and 4), however, at the protein level, we found only 
PMCA1 with some PMCA4 expression in MCF-7 cells. By using an isoform specific 
antibody which clearly recognized overexpressed PMCA2b in COS-7 cells, we could not 
detect any PMCA2 protein expression in MCF-7 cells. 
PMCAs are needed to restore the low level of intracellular Ca2+ concentration after 
stimulus and thus, changes in their expression could substantially alter the amplitude and 
duration of the Ca2+ signal. Our studies show a remarkable enhancement of PMCA4b 
expression during the differentiation of MCF-7 cells induced by a combined treatment with 
valerate and PMA; the PMCA4b mRNA level showed more than 30-fold elevation while the 
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protein expression increased over 500-fold. Moreover, the overall PMCA content (PMCA1 
and 4) of cells was increased more than 10-fold. 
SAHA and valproate, which are FDA-approved epigenetic drugs, also induced PMCA4b 
upregulation in our experiments. SAHA (Vorinostat) is a currently approved agent against 
cutaneous T-cell lymphoma, and clinical trials are ongoing against breast cancer and other 
solid tumors or hematological malignancies [17, 64]. Valproate was used primarily as an 
anticonvulsant and mood-stabilizing drug, but now, mostly in combination with other 
therapeutic agents, it is being tested in clinical studies for cancer treatment [17, 65]. 
Modulation of PMCA expression during HDACi-treatments may be an important step in the 
mode of action of these anticancer agents. 
Further confocal imaging studies showed that the newly synthesized pump is located 
mainly in the plasma membrane and therefore is expected to be functional. In good correlation 
with the increased plasma membrane expression of the pump we detected enhanced Ca2+ 
clearance from stimulated MCF-7 cells. Similarly, when PMCA4b was overexpressed in non-
treated MCF-7 cells, the Ca2+ signal returned more quickly to the baseline level than in the 
control cells, underlining the importance of PMCA4b in Ca2+ clearance from the 
differentiated cells. 
The role of PMCA4 in Ca2+ signaling has been studied in several other cancer cell lines 
using an siRNA silencing approach. Knocking down PMCA4 intensified the agonist-induced 
Ca2+ signal in HT-29 colon cancer cells [14].  However, when individual PMCA isoforms 
were knocked down in MDA-MB-231 breast cancer cells, silencing of PMCA4 did not 
change the Ca2+ signals evoked by different agents. In these cells PMCA1 silencing, on the 
other hand, markedly altered Ca2+ signaling indicating that PMCA1 was the main regulator of 
global Ca2+ signals [66] in undifferentiated cells. 
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PMCA4b is also known to interact with several signal and scaffold proteins which may 
connect this PMCA variant to specific signalling pathways [2]. As an example, the second 
intracellular loop of PMCA4b was shown to interact with the proapoptotic tumor supressor 
RASSF1 that may negatively regulate the EGF-induced ERK activation [67]. Calcineurin, a 
regulator of NFAT signaling, was also found to bind to PMCA4b that resulted in suppressed 
NFAT transcription in HEK293 cells [68]. On the other hand, PMCA4b binding to the α-1 
syntrophin and nitric oxide synthase I can form a ternary complex, that modulates NO 
production and signaling in mouse heart tissue [68], in cerebellar granule cells [69, 70] and in 
osteoclast differentiation [71]. Through the C-terminal tail, PMCA4b can bind to several PDZ 
proteins, such as SAP90/PSD95, SAP97, SAP102 [72], the Ania-3/Homer scaffold protein 
[73], that may arrange PMCA into specific membrane domains to regulate local Ca2+ 
signaling. More recently, PMCA4 was shown to interact with STIM1 that influenced T-cell 
activation  throught the activition of NFAT [74]. 
Importantly, PMCA4 expression could be detected in normal, fully differentiated breast 
epithelial tissue indicating that PMCA4b is an essential element of the Ca2+ homeostasis and 
probably other signalling pathways of the fully differentiated breast epithelium. These data 
together with the selective upregulation of PMCA4b expression during the differentiation of 
MCF-7 cells suggest that PMCA4b is connected to the differentiation program; and 
consequently, insufficient PMCA4b expression may contribute to the development and/or 
further progression of breast tumors. Remodeling of Ca2+ homeostasis in cancer cells is a 
hallmark of tumor progression and our findings support the idea that PMCA4b is essentially 
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Fig. 1. SCFAs and PMA induce upregulation of PMCA4b protein expression in MCF-7 cells. 
(A-D) Concentration dependent effects of treatments. MCF-7 cells were treated with the 
indicated amounts of butyrate (A), phenylbutyrate (B), valerate (C) or PMA (D) for 5 days, 
and PMCA protein expression from total cell lysates (20 μg protein per sample) was analyzed 
by Western blotting with anti-pan PMCA (5F10), anti-PMCA1 (PA1-914) and anti-PMCA4b 
(JA3) antibodies. Na,K-ATPase served as a loading control. A mixed sample was loaded onto 
the gels as a positive control. This consisted of microsomal membrane protein obtained from 
COS-7 cells (1 μg; this marked the position of PMCA1) mixed with microsomal membrane 
protein from COS-7 cells transfected with the PMCA4b constructs (0.05 μg; this marked 
PMCA4b). (E) Time course of PMCA4b expression during different treatments (5 mM 
butyrate, phenylbutyrate (PB) or valerate, or 10 nM PMA as indicated) for up to 5 days. (F-G) 
Densitometric analysis of PMCA4b (F) and total PMCA (G) expression after a 5 day 
treatment. Data were normalized to the expression levels of Na,K-ATPase and expressed as 
fold increase over the untreated controls. Bars represent means ± SD from three to five 
independent experiments. 
 
Fig. 2. SCFA and PMA treatments inhibit cell proliferation, and induce differentiation of 
MCF-7 cells. (A-B) Effects of treatments on proliferation. (A) Equal numbers of MCF-7 cells 
were treated with the indicated amounts of compounds, and numbers of viable cells were 
counted after 4 days of treatments. Values are means ± SD from two independent 
experiments, each having three replicates. (B) Time course of proliferation after 2 mM 
valerate ± 10 nM PMA treatments. (C-E) Effects of treatments on differentiation. (C) Cells 
were treated with the indicated differentiating agents for 4 days and lipid droplets were 
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stained with Oil Red O. Oil Red O fluorescence was analyzed by using the ImageJ software. 
Total areas of lipid droplets per total cell numbers were calculated. Bars represent means ± 
SD of eight representative pictures per treatment from two independent experiments. 
Significance is denoted by *** (P<0.001); two-tailed unpaired t-test. (D) Time course of 
differentiation after 2 mM valerate ± 10 nM PMA treatments. (E) Representative phase 
contrast and fluorescent images of 2 mM valerate ± 10 nM PMA-treated cells.  
 
Fig 3. Treatment with valerate in combination with PMA further increases the expression of 
PMCA4b. (A) Immunoblots of valerate ± PMA-treated cells. MCF-7 cells were treated with 2 
mM valerate or 10 nM PMA alone, or with 2 mM valerate in combination with 10 nM PMA 
up to 3 days. Equal amounts of cell lysates (15 μg of protein) were analyzed by Western blot. 
PMCA and SERCA expressions were determined using anti-pan PMCA (5F10), anti-
PMCA4b (JA3), anti-SERCA2 (IID8) or anti-SERCA3 (PL/IM430) antibodies. Na,K-ATPase 
served as a loading control. (B-C) Densitometric analysis of PMCA4b (B) and total PMCA 
(C) expression after 3 days of treatment. Data were normalized to the expression levels of 
Na,K-ATPase and expressed as fold increase over the untreated controls. Bars represent 
means ± SD from five independent experiments. (D)  Time course of PMCA4b expression. 
Values represent means ± SD from two independent experiments. (E) Detection of different 
PMCA isoforms by immunoprecipitation. Cells were treated with 2 mM valerate ± 10 nM 
PMA for 4 days, then lysed and proteins were immunoprecipitated with an anti-pan PMCA 
antibody (5F10). PMCA isoform expression was further analyzed by Western blot with 
isoform-specific antibodies. Equal volumes of input (7.5 μl) and immunoprecipitated samples 
(15 μl) were loaded onto the gel and proteins were detected with specific antibodies for all 
PMCA isoforms (NR1, NR2, NR3 and JA3 for PMCA1, 2, 3 and 4, respectively). 
Microsomal membrane preparations isolated from COS-7 cells were used as isoform-specific 
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positive controls. For PMCA1 the endogenous protein expression was detected  (1 μg of 
microsomal membrane protein) while in the case of the other PMCA isoforms COS-7 cells 
were transiently transfected with the PMCA2, PMCA3 or PMCA4b constructs and 0.5 μg (for 
PMCA2 and 3) or 0.05 μg (for PMCA4b) of microsomal membrane protein were loaded onto 
the gel. (F) Relative mRNA expression of PMCA isoforms in 2 mM valerate ± 10 nM PMA-
treated cells. All data are expressed as fold change in mRNA levels relative to the untreated 
controls after normalization to RPLP0 and POLR2A endogenous reference genes. Bars 
represent means ± SD from three independent experiments, each having three technical 
replicates. Significances between untreated control cells and treated cells are denoted by ** 
(P<0.01), * (P<0.05) or n.s. (not significant); two-tailed paired t-test. (G) Effects of PKC 
inhibitor treatment on PMCA4b upregulation in valerate ± PMA-treated cells. Cells were 
pretreated with 1 μM GF 109203X 1 hour before the addition of valerate and/or PMA, and 
after 4 days of treatment PMCA4b expression from total cell lysates (10 μg protein per 
sample) was analyzed by Western blotting with antibody JA3. In order to make the inhibition 
visible in each case, control samples (expressing much lower amounts of PMCA4b) were 
developed with a longer exposure time while valerate + PMA-treated samples were developed 
with a shorter exposure time than valerate- or PMA-treated samples. Inhibition is expressed as 
percent of original. Data are mean ± SD of densitometrically analyzed Western blots from two 
independent experiments. 
 
Fig. 4. (A) Upregulation of PMCA4 is specific for the PMCA4b isoform. Total cell lysates 
(10 μg protein per sample) from valerate ± PMA-treated cells were analyzed by Western 
blotting with anti-PMCA4b (JA3) and anti-PMCA4 (JA9) antibodies. A mixed sample of 
microsomal membrane protein obtained from COS-7 cells transfected with the PMCA4a 
construct (0.25 μg) and with the PMCA4b construct (0.05 μg) was loaded onto the gels as a 
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positive control. (B) PMCA4b shows clear plasma membrane localization. Cells were treated 
with 2 mM valerate ± 10 nM PMA for 4 days, then cells were immunostained with either anti-
PMCA4b (JA3) or anti-PMCA4 (JA9) and anti-Na,K-ATPase antibodies, and images were 
taken by confocal microscopy. Scale bar, 50 µm. 
 
Fig. 5. SAHA and valproate (VPA) induce upregulation of PMCA4b protein expression in 
MCF-7 cells. (A and C) Concentration-dependent effects of treatments. Cells were treated 
with the indicated amounts of SAHA (A) or VPA (C) alone, or in combination with 10 nM 
PMA for 4 days, and protein expression from total cell lysates (10 μg protein per sample) was 
analyzed by Western blotting with anti-PMCA4b (JA3) and anti-PMCA1 (PA1-914) 
antibodies. Na,K-ATPase served as a loading control, as above. (B and D) Densitometric 
analysis for PMCA4b expression after SAHA (B) or VPA (D) treatments. Data were 
normalized to the expression levels of Na,K-ATPase and expressed as fold increase over the 
untreated controls. Bars represent means ± SD from three independent experiments. 
 
Fig. 6. Enhanced PMCA4b expression diminishes intracellular Ca2+ signaling in differentiated 
GCaMP2-MCF-7 cells. (A) MCF-7 cells were stably transfected with the GCaMP2 Ca2+ 
sensor (GCaMP2-MCF-7 cells) and Ca2+ signals were detected by confocal microscopy. (B) 
Western blot analysis of PMCA4b expression from whole cell lysates of GCaMP2-MCF-7 
cells. Cells were either differentiated with the indicated amounts of compounds or transiently 
transfected with the mCherry-PMCA4x/b construct, and equal amounts of cell lysates (5 μg of 
protein) were loaded onto the gel. Expression of PMCA4b was analyzed with an anti-
PMCA4b antibody (JA3). Na,K-ATPase served as a loading control. (C) Ca2+ signal 
measurements in differentiated GCaMP2-MCF-7 cells. Cells were treated with 2 mM valerate 
alone or in combination with 10 nM PMA for 3 days, then the medium was replaced by fresh 
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DMEM and cells were incubated in the absence of differentiating compounds for an 
additional 24 hours. To test Ca2+ signaling using internal sources of Ca2+ the culture medium 
was replaced by Ca2+ free HBSS and intracellular stores were challenged by the addition of 2 
μM thapsigargin (Tg) and 100 μM ATP, as indicated. After 5 minutes the external Ca2+ was 
restored to 2mM and Ca2+ influx through store-operated Ca2+ channels was followed for 
another 10 minutes by confocal imaging. Data represent means of normalized values (F/F0) ± 
95% CI of about 50 to 70 cells collected from three independent experiments. (D) 
Intracellular Ca2+ signals evoked by the Ca2+ ionophore A23187 in valerate ± PMA treated 
GCaMP2-MCF-7 cells. Before initiating the Ca2+ signal, culture medium was replaced by 
HBSS supplemented with 2 mM Ca2+ and Ca2+ influx was triggered by A23187, as indicated. 
Data represent means of normalized values (F/F0) ± 95% CI of about 15 to 25 cells. (E) 
Representative confocal images of PMCA4 expression in GCaMP2-MCF-7 cells after the 
Ca2+ signal measurement. Cells were fixed and immunostained with anti-PMCA4 antibody 
(JA9). Scale bar, 50 µm. 
 
Fig. 7. Overexpression of mCherry-PMCA4x/b leads to increased Ca2+ clearance after 
stimulation in GCaMP2-MCF-7 cells. (A) Representative confocal images of mCherry-
PMCA4x/b expression in transiently transfected GCaMP2-MCF-7 cells. Scale bar, 20 µm. (B) 
Ca2+ signaling in GCaMP2-MCF-7 cells transiently expressing the mCherry-PMCA4x/b 
construct. Before initiating the Ca2+ signal, culture medium was replaced by Ca2+ free HBSS, 
and then 2 μM thapsigargin (Tg) and 100 μM ATP were added. After 5 minutes of incubation, 
when the internal Ca2+ stores were depleted, external Ca2+ was restored to 2mM, and Ca2+ 
influx was followed for another 10 minutes. Data represent means of normalized values (F/F0) 
± 95% CI of about 25 to 40 cells from four independent experiments. (C) Half peak decay 
time of the second phase of the transients (SOCE) in differentiated and mCherry-PMCA4x/b 
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overexpressing cells. Bar graphs are means ± SD from three or four independent experiments. 
Significances between control and PMCA4b expressing cells are denoted by * (P<0.05); two-
tailed unpaired t-test. (D) Intracellular Ca2+ signals evoked by the Ca2+ ionophore A23187 in 
mCherry-PMCA4x/b transfected GCaMP2-MCF-7 cells. Before initiating the Ca2+ signal, 
culture medium was replaced by HBSS supplemented with 2 mM Ca2+ and Ca2+ influx was 
triggered by A23187, as indicated. Data represent means of normalized values (F/F0) ± 95% 
CI of about 10 cells. 
 
Fig. 8. Immunohistochemical detection of PMCA4 in normal breast tissue. Tissue sections 
from archival normal human mammary gland specimens were stained with the anti-PMCA4 
antibody (JA9), and signal was visualized using an indirect avidin-biotin-peroxydase 
detection system with 3,3`diaminobenzidine as chromogen. Slides were counterstained with 
hematoxylin. Brown staining in mammary ductal epithelium indicates PMCA4 expression in 
a plasma membrane location. A representative image of four different samples is shown. 
Staining with isotype-matched negative control antibody was negative. 
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